Search Results
ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study
ESMO 2020 Highlights on pembrolizumab in LA-HNSCC: The GORTEC 2015-01 “PembroRad” study
Updates in 1L urothelial cancer from ESMO 2020
ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study
ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005
ESMO 2020 Highlights on neoadjuvant ICI in early TNBC: The IMpassion031 study
ESMO 2020 Expert Video Report on the combination of immuno and targeted therapies in melanoma
First-line pembrolizumab combination fails to boost advanced urothelial cancer survival | Ajjai Alva
Immunotherapy trial updates in NSCLC from ESMO 2020
ESMO highlights: genitourinary cancers
ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study
